ASCO 2022 | QoL in response adaptive de-escalated therapy following nivo-based induction in oropharyngeal cancer

Ari Rosenberg, MD, University of Chicago, Chicago, IL, outlines the findings of the investigator-initiated OPTIMA II trial (NCT02258659), which assessed the impact of de-escalated local therapy following anti-PD1 based induction on the quality of life (QoL) of patients with locoregionally advanced human papillomavirus-associated (HPV+) oropharyngeal cancer (OPC). Specifically, during the study, patients were treated with nivolumab with nab-paclitaxel and carboplatin, followed by response adaptive de-intensified treatment. This response adaptive de-escalated treatment regime was found to improve the QoL of patients with locoregionally advanced HPV+ OPC across several domains. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.